Listed

Turning Point Brands, Inc.: Form 10-Q for the period ended Sep 30, 2019

Filed with the SEC on Nov 4, 2019 and accepted by EDGAR at Nov 4, 2019, 17:15 ET.

Share

Management's discussion and analysis

As filed, 46,046 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

You should read the following discussion of the historical financial condition and results of operations in conjunction with our historical consolidated financial statements and accompanying notes, which are included elsewhere in this Quarterly Report on Form 10-Q. In addition, this discussion includes forward-looking statements subject to risks and uncertainties that may result in actual results differing from statements we make. See “Cautionary Note Regarding Forward-Looking Statements.” Factors that could cause actual results to differ include those risks and uncertainties discussed in “Risk Factors.”

The following discussion relates to the unaudited financial statements of Turning Point Brands, Inc., included elsewhere in this Quarterly Report on Form 10-Q. In this discussion, unless the context requires otherwise, references to “our Company” “we,” “our,” or “us” refer to Turning Point Brands, Inc., and its consolidated subsidiaries. References to “TPB” refer to Turning Point Brands, Inc., without any of its subsidiaries. We were incorporated in 2004 under the name North Atlantic Holding Company, Inc. On November 4, 2015, we changed our name to Turning Point Brands, Inc. Many of the amounts and percentages in this discussion have been rounded for convenience of presentation.

Organizational Structure

We, Turning Point Brands, Inc., are a holding company which owns North Atlantic Trading Company, Inc. (“NATC”), and its subsidiaries, Turning Point Brands, LLC (“TPLLC”), and its subsidiaries, and Turning Point Brands (Canada) Inc. (“TPBC”). NATC includes subsidiaries National Tobacco Company, L.P. (“NTC”), National Tobacco Finance, LLC (“NTFLLC”), North Atlantic Operating Company, Inc. (“NAOC”), North Atlantic Cigarette Company, Inc. (“NACC”), and RBJ Sales, Inc. (“RBJ”). TPLLC includes subsidiaries Intrepid Brands, LLC (“Intrepid”), Vapor Beast, LLC (“VaporBeast”, f/k/a Smoke Free Technologies, Inc.), Vapor Shark, LLC, and its subsidiaries (collectively, “Vapor Shark”, f/k/a The Hand Media), Vapor Acquisitions Company, LLC (“Vapor Supply”), Vapor Finance, LLC (“VFIN”), International Vapor Group, LLC and its subsidiaries (collectively, “IVG”), and Nu-X Ventures, LLC (“Nu-X”).

Overview

Turning Point Brands, Inc. (the “Company,” “we,” “our,” or “us”) is a leading, independent provider of Other Tobacco Products (“OTP”) and adult consumer alternatives. We estimate the OTP industry generated approximately $11 billion of manufacturer revenue in 2018. In contrast to manufactured cigarettes, which have been experiencing declining volumes for decades based on data published by the Alcohol and Tobacco Tax and Trade Bureau (“TTB”), the OTP industry is demonstrating increased consumer appeal with low to mid-single digit consumer unit growth as reported by Management Science Associates, Inc. (“MSAi”), a third-party analytics and information company. We were the 6th largest competitor in terms of total OTP consumer units sold during 2018. We sell a wide range of products across the OTP spectrum; however, we do not sell cigarettes. Our portfolio of brands includes some of the most widely recognized names in the OTP industry, such as Zig-Zag®, Beech-Nut®, Stoker’s®, Trophy®, VaporBeast® and VaporFi®. We currently ship to approximately 800 distributors with an additional 100 secondary, indirect wholesalers in the U.S. that carry and sell our products. We operate in three segments: (i) Smokeless products, (ii) Smoking products, and (iii) NewGen products. Under the leadership of a senior management team with an average of 23 years of experience in the tobacco industry, we have grown and diversified our business through new product launches, category expansions, and acquisitions while concurrently improving operational efficiency.

We have identified additional growth opportunities in the emerging alternatives market. In January 2019, we established our subsidiary, Nu-X Ventures (“Nu-X”), a new company and wholly-owned subsidiary dedicated to the development, production and sale of alternative products and acquisitions in related spaces. The creation of Nu-X allows TPB to leverage its expertise in traditional OTP management to alternative products. The TPB management team has over 100 years of experience navigating federal, state and local regulations that are directly applicable to the growing alternatives market. In July 2019, we acquired a 30% stake in ReCreation Marketing (“ReCreation). ReCreation is a specialty marketing and distribution firm focused on building brands in the Canadian smoking, vaping and alternative products categories. The investment will leverage ReCreation’s significant expertise in marketing and distributing tobacco and cannabis products throughout Canada. In November 2018, we acquired a minority stake in Canadian American Standard Hemp Inc. (“CASH”). The investment in CASH positions us to meaningfully participate in the market for hemp-derived products. Through our investment in CASH, we have access to CASH’s proprietary extraction processes enabling the harvest of cannabinoids for use in the creation and distribution of high-quality hemp-derived products. Both investments are part of Nu-X and we plan to make additional investments, partnerships and acquisitions to drive the business of Nu-X. These endeavors will enable us to continue to identify unmet customer needs and provide quality products that we believe will result in genuine customer satisfaction and foster the growth of revenue.

We believe there are meaningful opportunities to grow through acquisitions and joint ventures across all product categories. As of December 31, 2018, our products are available in approximately 185,000 U.S. retail locations which, with the addition of retail stores in Canada, brings our total North American retail presence to an estimated 210,000 points of distribution. Our sales team targets widespread distribution to all traditional retail channels, including convenience stores.

Products

We operate in three segments: Smokeless products, Smoking products and NewGen products. In our Smokeless products segment, we (i) manufacture and market moist snuff and (ii) contract for and market loose leaf chewing tobacco products. In our Smoking products segment, we (i) market and distribute cigarette papers, tubes, and related products; (ii) market and distribute finished cigars and MYO cigar wraps; and (iii) process, package, market, and distribute traditional pipe tobaccos. In our NewGen products segment, we (i) market and distribute e-cigarettes, e-liquids, vaporizers, and certain other products without tobacco and/or nicotine; (ii) market and distribute a wide assortment of vaping and CBD related products to non-traditional retail via VaporBeast, Vapor Shark, Vapor Supply, IVG and Solace; and (iii) market and distribute a wide assortment of vaping and CBD related products to individual consumers via Vapor Shark and VaporFi branded retail outlets in addition to online platforms. Our portfolio of brands includes some of the most widely recognized names in the OTP industry such as Stoker’s® in the Smokeless segment, Zig-Zag® in the Smoking segment, and VaporBeast® and VaporFi® in the NewGen segment.

Operations

Our core tobacco business (Smokeless and Smoking segments) primarily generates revenues from the sale of our products to wholesale distributors who, in turn, resell the products to retail operations. Our acquisition of VaporBeast in the fourth quarter of 2016 expanded our revenue streams as we began selling directly to non-traditional retail outlets. Our acquisitions of Vapor Shark in the second quarter of 2017 and Vapor Supply in the second quarter of 2018 further expanded our selling network by allowing us to directly reach ultimate consumers through Vapor Shark branded retail outlets. Our acquisition of IVG in the third quarter of 2018 enhanced our business-to-consumer revenue stream with the addition of Vapor-Fi branded retail outlets accompanying a robust online platform headlined by VaporFi.com and DirectVapor.com. Our net sales, which include federal excise taxes, consist of gross sales net of cash discounts, returns, and selling and marketing allowances.

We rely on long-standing relationships with high-quality, established manufacturers to provide the majority of our produced products. Approximately 85% of our production, as measured by net sales, is outsourced to suppliers. The remaining production consists of our moist snuff tobacco operations located in Dresden, Tennessee, and Louisville, Kentucky; the packaging of our pipe tobacco in Louisville, Kentucky; and the proprietary e-liquids operations located in Louisville, Kentucky, and Miami, Florida. Our principal operating expenses include the cost of raw materials used to manufacture the limited number of our products which we produce in-house; the cost of finished products, which are generally purchased goods; federal excise taxes; legal expenses; and compensation expenses, including benefits and costs of salaried personnel. Our other principal expenses include interest expense and other expenses.

Key Factors Affecting Our Results of Operations

We consider the following to be the key factors affecting our results of operations:

  • Our ability to further penetrate markets with our existing products;
  • Our ability to introduce new products and product lines that complement our core business;
  • Decreasing interest in some tobacco products among consumers;
  • Price sensitivity in our end-markets;
  • Marketing and promotional initiatives, which cause variability in our results;
  • General economic conditions, including consumer access to disposable income;
  • Cost and increasing regulation of promotional and advertising activities;
  • Cost of complying with regulation, including the Remedy Order;
  • Counterfeit and other illegal products in our end-markets;
  • Currency fluctuations;
  • Our ability to identify attractive acquisition opportunities in OTP; and
  • Our ability to integrate acquisitions.

Recent Developments

The Board of Directors is reviewing strategic alternatives for our third-party vaping distribution business. We are committed to capitalizing on our core competencies in branding, distribution, product development, and regulatory affairs to create market-leading adult actives products. This includes investing in the FDA PMTA process for our proprietary brands. However, we believe the expected future returns from third-party vaping distribution may not justify the required investment of human and financial resources going forward. There can be no assurance that this process will result in the approval or completion of any particular strategic alternative or transaction in the future.

Solace Technologies Acquisition

In July 2019, we acquired the assets of E-Vape 12, Inc and Solace Technologies LLC (“Solace”) for $8.0 million in total consideration, comprised of $7.7 million in cash and $0.5 million holdback for 18 months. As additional consideration, we will issue, to the former owners, stock equal to $2.31 million upon the achievement of certain annual milestones. In addition, 88.582 performance based restricted stock with a fair value of $4.62 million was issued to former owners who became employees. See Note 15, “Share Incentive Plans” for further information. Solace is an innovative product development company that has grown from the creator of one of the leading vape juice brands in the industry into a leader of alternative ingredients product development. We intend to incorporate Solace’s innovative products as well as the legacy vapor products into our Nu-X Ventures development engine.

ReCreation Marketing Investment

In July 2019 we obtained a 30% stake in Canadian distribution entity, ReCreation Marketing (“ReCreation”). We may invest $3 million through our newly-created subsidiary, Turning Point Brands (Canada) Inc., into ReCreation, with options to acquire up to a 50% ownership position. We will receive board seats aligned with our ownership position.

ReCreation Marketing is a specialty marketing and distribution firm focused on building brands in the Canadian smoking, vaping and alternative products categories. ReCreation’s management has significant expertise in marketing and distributing tobacco and cannabis products throughout Canada. ReCreation’s management and advisory team has over 50 years combined experience building and managing a portfolio of premium brands, all supported by an expert team of sales associates working across Canada to provide service to over 30,000 traditional retail outlets and newly-constructed cannabis dispensaries.

Convertible Notes Offering

Refer to Note 11, “Notes Payable and Long-term Debt”, of Notes to Consolidated Financial Statements for discussion regarding our Convertible Senior Notes issued in July 2019.

Critical Accounting Policies and Uses of Estimates

There have been no material changes to our critical accounting policies and estimates from the information provided in “Management’s Discussion and Analysis of Financial Condition and Results of Operations” included in our 2018 Annual Report on Form 10-K.

Recent Accounting Pronouncements

Refer to Note 2, “Summary of Significant Accounting Policies”, of Notes to Consolidated Financial Statements included in this Quarterly Report for a description of recently issued accounting pronouncements, including those recently adopted.

Results of Operations

Comparison of the Three Months Ended September 30, 2019, to the Three Months Ended September 30, 2018

The table and discussion set forth below displays our consolidated results of operations (in thousands):

Consolidated Results of Operations Data: Net sales Three Months Ended September 30, 2019 2018 % Change
Smokeless products $26,187 $21,743 20.4%
Smoking products 30,222 28,079 7.6%
NewGen products 40,391 33,527 20.5%
Total net sales 96,800 83,349 16.1%
Cost of sales 53,984 47,138 14.5%
Gross profit
Smokeless products 13,587 11,020 23.3%
Smoking products 16,619 14,814 12.2%
NewGen products 12,610 10,377 21.5%
Total gross profit 42,816 36,211 18.2%
Selling, general, and administrative expenses 29,784 23,253 28.1%
Operating income 13,032 12,958 0.6%
Interest expense, net 3,641 3,702 -1.6%
Investment Income (265) (89) 197.8%
Loss on extinguishment of debt 1,158 - NM
Net periodic income, excluding service cost (12) (45) -73.3%
Income before income taxes 8,510 9,390 -9.4%
Income tax expense 2,236 1,436 55.7%
Consolidated net income $6,274 $7,954 -21.1%

Net Sales: For the three months ended September 30, 2019, consolidated net sales increased to $96.8 million from $83.3 million for the three months ended September 30, 2018, an increase of $13.5 million or 16.1%. The increase in net sales was primarily driven by volume across all segments in 2019.

For the three months ended September 30, 2019, net sales in the Smokeless products segment increased to $26.2 million from $21.7 million for the three months ended September 30, 2018, an increase of $4.4 million or 20.4%. For the three months ended September 30, 2019, volume increased 15.1% and price/mix increased 5.3%. The increase in net sales was primarily driven by the continuing double-digit volume growth of Stoker’s® MST partially offset by declining sales in chewing tobacco, largely attributable to long-term segment erosion, and a continuing shift to lower price products.

For the three months ended September 30, 2019, net sales in the Smoking products segment increased to $30.2 million from $28.1 million for the three months ended September 30, 2018, an increase of $2.1 million or 7.6%. For the three months ended September 30, 2019, volume increased 3.6% and price/mix increased 4.0%. The increase in net sales is primarily related to increased wrap sales.

For the three months ended September 30, 2019, net sales in the NewGen products segment increased to $40.4 million from $33.5 million for the three months ended September 30, 2018, an increase of $6.9 million or 20.5%. The increase in net sales was primarily driven by $6.3 million of Nu-X alternative products sales in the quarter (which includes our acquisition of Solace) and an additional two months of IVG net sales in 2019, offset by declines in the existing vapor businesses in September.

Gross Profit: For the three months ended September 30, 2019, consolidated gross profit increased to $42.8 million from $36.2 million for the three months ended September 30, 2018, an increase of $6.6 million or 18.2%. Gross profit as a percentage of revenue increased to 44.2% for the three months ended September 30, 2019, compared to 43.4% for the three months ended September 30, 2018.

For the three months ended September 30, 2019, gross profit in the Smokeless products segment increased to $13.6 million from $11.0 million for the three months ended September 30, 2018, an increase of $2.6 million or 23.3%. Gross profit as a percentage of net sales increased to 51.9% of net sales for the three months ended September 30, 2019, from 50.7% of net sales for the three months ended September 30, 2018, primarily as a result of increased MST volume.

For the three months ended September 30, 2019, gross profit in the Smoking products segment increased to $16.6 million from $14.8 million for the three months ended September 30, 2018, an increase of $1.8 million or 12.2%. Gross profit as a percentage of net sales increased to 55.0% of net sales for the three months ended September 30, 2019, from 52.8% of net sales for the three months ended September 30, 2018, as a result of increased wrap sales and a continued decline in the low margin cigar business. For the three months ended September 30, 2019 cigar sales were $1.0 million compared to $1.3 million for the three months ended September 30, 2018.

For the three months ended September 30, 2019, gross profit in the NewGen products segment increased to $12.6 million from $10.4 million for the three months ended September 30, 2018, an increase of $2.2 million or 21.5%. Gross profit as a percentage of net sales increased to 31.2% of net sales for the three months ended September 30, 2019, from 31.0% of net sales for the three months ended September 30, 2018, primarily as a result of the addition of proprietary Nu-X CBD and IVG, a business-to-consumer operation which generally has higher margins. For the three months ended September 30, 2019, gross profit included $2.6 million of tariff expenses.

Selling, General, and Administrative Expenses: For the three months ended September 30, 2019, selling, general, and administrative expenses increased to $29.8 million from $23.3 million for the three months ended September 30, 2018, an increase of $6.5 million or 28.1%. Selling, general and administrative expenses in the three months ended September 20, 2019, included $3.7 million of expense relating to the inclusion of an additional two months of IVG activity, $2.0 million of new product launch costs for Nu-X products and $1.0 million of stock options, restricted stock and incentives expense. The increased expenses were offset by $0.6 million less transactional costs for the three months ended September 30, 2019 as compared to three months ended September 30, 2018.

Interest Expense, net: For the three months ended September 30, 2019, interest expense, net decreased to $3.6 million as a result of the interest on the Convertible Senior Notes, offset by the reduction of interest from the Second Lien Credit Facility and the increased cash deposits from proceeds of the Convertible Senior Notes receiving interest from $3.7 million for the three months ended September 30, 2018.

Investment Income: For the three months ended September 30, 2019, investment income relating to investment of the MSA escrow deposits increased to $0.3 million from $0.1 million for the three months ended September 30, 2018.

Loss on extinguishment of debt: For the three months ended September 30, 2019, there was a loss on the extinguishment of debt for $1.2 million related to paying off the 2018 Second Lien Credit Facility. For the three months ended September 30, 2018, there was no gain or loss on extinguishment of debt.

Net Periodic Income: Net periodic income was less than $0.1 million for the three months ended September 30, 2019 and September 30, 2018.

Income Tax Expense: Our income tax expense of $2.2 million was 26.3% of income before income taxes for the three months ended September 30, 2019. Our effective income tax rate of 15.3% for the three months ended September 30, 2018 included a discrete tax deduction of $3.3 million relating to stock option exercises.

Consolidated Net Income: Due to the factors described above, consolidated net income for the three months ended September 30, 2019 and 2018, was $6.3 million and $8.0 million, respectively.

Comparison of the Nine months Ended September 30, 2019, to the Nine months Ended September 30, 2018

The table and discussion set forth below displays our consolidated results of operations (in thousands):

Consolidated Results of Operations Data: Net sales Nine Months Ended September 30, 2019 2018 % Change
Smokeless products $74,907 $66,900 12.0%
Smoking products 81,104 84,403 -3.9%
NewGen products 125,756 87,089 44.4%
Total net sales 281,767 238,392 18.2%
Cost of sales 157,304 134,577 16.9%
Gross profit
Smokeless products 39,723 34,546 15.0%
Smoking products 43,841 43,158 1.6%
NewGen products 40,899 26,111 56.6%
Total gross profit 124,463 103,815 19.9%
Selling, general, and administrative expenses 79,455 66,314 19.8%
Operating income 45,008 37,501 20.0%
Interest expense, net 11,233 10,811 3.9%
Investment income (527) (328) 60.7%
Loss on extinguishment of debt 1,308 2,384 -45.1%
Net periodic benefit (income), excluding service cost (34) 176 -119.3%
Income before income taxes 33,028 24,458 35.0%
Income tax expense 6,989 4,153 68.3%
Consolidated net income 26,039 20,305 28.2%

Net Sales: For the nine months ended September 30, 2019, consolidated net sales increased to $281.8 million from $238.4 million for the nine months ended September 30, 2018, an increase of $43.4 million or 18.2%. The increase in net sales was primarily driven by volume growth in the NewGen segment which includes an additional eight months of IVG results in 2019, and sales from the newly launched Nu-X alternative products.

For the nine months ended September 30, 2019, net sales in the Smokeless products segment increased to $74.9 million from $66.9 million for the nine months ended September 30, 2018, an increase of $8.0 million or 12.0% primarily due to the continuing volume growth of Stoker’s® MST.

For the nine months ended September 30, 2019, net sales in the Smoking products segment decreased to $81.1 million from $84.4 million for the nine months ended September 30, 2018, a decrease of $3.3 million or 3.9%. The net sales decline is primarily attributable to the delay of Canadian paper orders in the first half of the year as a result of new packaging regulations in Canada and declining sales in the low-margins cigar business.

For the nine months ended September 30, 2019, net sales in the NewGen products segment increased to $125.8 million from $87.1 million for the nine months ended September 30, 2018, an increase of $38.7 million or 44.4%. The increase in net sales was primarily driven by $11.4 million of Nu-X alternative products sales year to date (including the Solace acquisition) and an additional eight months of IVG net sales in 2019.

Gross Profit: For the nine months ended September 30, 2019, consolidated gross profit increased to $124.5 million from $103.8 million for the nine months ended September 30, 2018, an increase of $20.6 million or 19.9%, primarily due to increased net sales. Gross profit as a percentage of revenue increased to 44.2% for the nine months ended September 30, 2019, from 43.5% for the nine months ended September 30, 2018, primarily due to higher margins in the Smokeless segment from increased MST volume and higher margins in the NewGen segment resulting from the addition of proprietary Nu-X CBD and IVG, a business-to-consumer operation which generally has higher margins.

For the nine months ended September 30, 2019, gross profit in the Smokeless products segment increased to $39.7 million from $34.5 million for the nine months ended September 30, 2018, an increase of $5.2 million or 15.0%. Gross profit as a percentage of net sales increased to 53.0% of net sales for the nine months ended September 30, 2019, from 51.6% of net sales for the nine months ended September 30, 2018. The increase in gross profit as a percentage of revenue is primarily due to efficiencies realized in the growing Stoker’s® MST line.

For the nine months ended September 30, 2019, gross profit in the Smoking products segment increased to $43.8 million from $43.2 million for the nine months ended September 30, 2018, an increase of $0.7 million or 1.6%. Gross profit as a percentage of net sales increased to 54.1% of net sales for the nine months ended September 30, 2019, from 51.1% of net sales for the nine months ended September 30, 2018, as a result of a continued decline in the low margin cigar business.

For the nine months ended September 30, 2019, gross profit in the NewGen products segment increased to $40.9 million from $26.1 million for the nine months ended September 30, 2018, an increase of $14.8 million or 56.6%. Gross profit as a percentage of net sales increased to 32.5% of net sales for the nine months ended September 30, 2019, from 30.0% of net sales for the nine months ended September 30, 2018, primarily as a result of the addition of proprietary Nu-X CBD and IVG, a business-to-consumer operation which generally has higher margins. For the nine months ended September 30, 2019, gross profit included $6.6 million of tariff expenses.

Selling, General, and Administrative Expenses: For the nine months ended September 30, 2019, selling, general, and administrative expenses increased to $79.5 million from $66.3 million for the nine months ended September 30, 2018, an increase of $13.1 million or 19.8%, The increase was related to $13.9 million of an additional eight months of IVG expenses, $2.2 million additional compensation expense related to stock options, restricted stock and incentives expense, and $3.7 million additional new product launch costs for Nu-X products. The increased expenses are partially offset by a net $5.5 million gain related to the settlement of the VMR Distribution and Supply agreement (VMR Agreement) during the second quarter 2019, as well as $1.0 million less of transactional costs. Refer to Note 17, “Legal Settlement”, of Notes to Consolidated Financial Statements for additional information on the settlement.

Interest Expense, net: For the nine months ended September 30, 2019, interest expense increased to $11.2 million from $10.9 million for the nine months ended September 30, 2018, as a result of interest related to the Convertible Senior Notes as of September 30, 2019 offset by the reduction of interest from the Second Lien Credit Facility.

Investment Income: Investment income relating to investment of the MSA escrow deposits increased to $0.5 million for the nine months ended September 30, 2019, compared to $0.3 million for the nine months ended September 30, 2018.

Loss on Extinguishment of Debt: For the nine months ended September 30, 2019, loss on extinguishment of debt was $1.3 million primarily due to paying off the 2018 Second Lien Credit Facility. For the nine months ended September 30, 2018, loss on extinguishment of debt was $2.4 million as a result of refinancing our credit facility in the first quarter of 2018.

Net Periodic Benefit (Income): Net periodic income was less than $0.1 million for the nine months ended September 30, 2019, compared to net periodic benefit of $0.2 million for the nine months ended September 30, 2018.

Income Tax Expense: Our income tax expense of $7.0 million was 21.2% of income before income taxes for the nine months ended September 30, 2019. Our effective income tax rate of 17.0% for the nine months ended September 30, 2018 included discrete tax deductions of $5.2 million from the exercise of stock options.

Consolidated Net Income: Due to the factors described above, consolidated net income for the nine months ended September 30, 2019 and 2018, was $26.0 million and $20.3 million, respectively.

EBITDA and Adjusted EBITDA

To supplement our financial information presented in accordance with generally accepted accounting principles in the United States, or U.S. GAAP, we use non-U.S. GAAP financial measures including EBITDA and Adjusted EBITDA. We believe Adjusted EBITDA provides useful information to management and investors regarding certain financial and business trends relating to our financial condition and results of operations. Adjusted EBITDA is used by management to compare our performance to that of prior periods for trend analyses and planning purposes and is presented to our Board of Directors. We believe that EBITDA and Adjusted EBITDA are appropriate measures of operating performance because they eliminate the impact of expenses that do not relate to operating performance. In addition, our credit agreements contain financial covenants which use Adjusted EBITDA calculations.

We define “EBITDA” as net income before interest expense, loss on extinguishment of debt, provision for income taxes, depreciation, and amortization. We define “Adjusted EBITDA” as net income before interest expense, loss on extinguishment of debt, provision for income taxes, depreciation, amortization, other non-cash items, and other items we do not consider ordinary course in our evaluation of ongoing operating performance.

Non-U.S. GAAP measures should not be considered a substitute for, or superior to, financial measures calculated in accordance with U.S. GAAP. Adjusted EBITDA excludes significant expenses required to be recorded in our financial statements by U.S. GAAP and is subject to inherent limitations. Other companies in our industry may calculate this non-U.S. GAAP measure differently than we do or may not calculate it at all, limiting its usefulness as a comparative measure. The tables below provide reconciliations between net income and Adjusted EBITDA.

(in thousands)

Three Months Ended September 30, 2019 2018
Consolidated net income $6,274 $7,954
Add:
Interest expense, net 3,641 3,702
Loss on extinguishment of debt 1,158 -
Income tax expense 2,236 1,436
Depreciation expense 692 479
Amortization expense 356 206
EBITDA $14,357 $13,777
Components of Adjusted EBITDA
Other (a) 151 253
Stock options, restricted stock, and incentives expense (b) 1,314 367
Transactional expenses and strategic initiatives (c) 470 1,056
New product launch costs (d) 1,979 545
Product line rationalizations (e) - 301
Warehouse reorganization (f) 184 -
Severance charges and organizational development (g) 81 98
FDA PMTA (h) 241 70
Adjusted EBITDA $18,777 $16,467

(a) Represents LIFO adjustment, non-cash pension/ postretirement expense (income) and foreign exchange hedging.

(b) Represents non-cash stock options, restricted stock, incentives expense and Solace PRSUs.

(c) Represents the fees incurred for transaction expenses and strategic initiatives.

(d) Represents product launch costs of our new product lines.

(e) Represents costs associated with discontinued products related to product line rationalization.

(f) Represents costs associated with consolidating warehouses.

(g) Represents costs associated with departmental restructuring, primarily severance.

(h) Represents costs associated with applications related to the FDA PMTA.

(in thousands)

Nine Months Ended September 30, 2019 2018
Consolidated net income $26,039 $20,305
Add:
Interest expense, net 11,233 10,811
Loss on extinguishment of debt 1,308 2,384
Income tax expense 6,989 4,153
Depreciation expense 1,855 1,596
Amortization expense 1,079 557
EBITDA $48,503 $39,806
Components of Adjusted EBITDA
Other (a) (25) 468
Stock options, restricted stock, and incentives expense (b) 3,227 1,056
Transactional expenses and strategic initiatives (c) 1,567 2,596
New product launch costs (d) 3,691 1,227
Product line rationalizations (e) - 1,309
Warehouse reorganization (f) 692 -
Severance charges and organizational development (g) 727 778
Vendor settlement (h) (5,522) -
FDA PMTA (i) 241 159
Adjusted EBITDA $53,101 $47,399

(a) Represents LIFO adjustment, non-cash pension/ postretirement expense (income) and foreign exchange hedging.

(b) Represents non-cash stock options, restricted stock, incentives expense and Solace PRSUs.

(c) Represents the fees incurred for transaction expenses and strategic initiatives.

(d) Represents product launch costs of our new product lines.

(e) Represents costs associated with discontinued products related to product line rationalization.

(f) Represents costs associated with consolidating warehouses.

(g) Represents costs associated with departmental restructuring, primarily severance.

(h) Represents net gain associated with the settlement of a vendor contract.

(i) Represents costs associated with applications related to the FDA PMTA.

Liquidity and Capital Reserves

Our principal uses for cash are working capital, debt service, and capital expenditures. We believe our cash flows from operations and borrowing availability under our 2018 Revolving Credit Facility are adequate to satisfy our operating cash requirements for the foreseeable future.

Our working capital, which we define as current assets less current liabilities, increased $111.2 million to $159.3 million at September 30, 2019, compared with $48.1 million at December 31, 2018. The increase in working capital is primarily due to cash proceeds from the issuance of the Convertible Senior Notes.

(in thousands)

As of September 30, 2019 December 31, 2018
Current assets $202,561 $111,854
Current liabilities 43,257 63,766
Working capital $159,304 $48,088

43

Cash Flows from Operating Activities

For the nine months ended September 30, 2019, net cash provided by operating activities was $20.0 million compared to net cash provided by operating activities of $1.0 million for the nine months ended September 30, 2018, an increase of $19.0 million, primarily due to changes in working capital accounts and increased net income for the current period.

Cash Flows from Investing Activities

For the nine months ended September 30, 2019, net cash provided by investing activities was $16.6 million compared to net cash used in investing activities of $21.9 million for the nine months ended September 30, 2018, an increase of $38.6 million, primarily due to the change in MSA escrow deposits from investments to cash holdings as well as lower cash paid for acquisitions in the nine months ending September 30, 2019.

Cash Flows from Financing Activities

For the nine months ended September 30, 2019, net cash provided by financing activities was $70.9 million compared to net cash provided by financing activities of $16.7 million for the nine months ended September 30, 2018, an increase of $54.2 million, primarily due to the proceeds from the issuance of Convertible Senior Notes offset by payments on the 2018 Revolving Credit Facility, the 2018 Second Lien Credit Facility and payment for the call options.

Dividends

On November 9, 2017, our Board of Directors approved the initiation of a cash dividend to shareholders. The initial quarterly dividend of $0.04 per common share was paid on December 15, 2017, to shareholders of record at the close of business on November 27, 2017. The most recent dividend of $0.045 per common share was paid on October 11, 2019, to shareholders of record at the close of business on September 20, 2019.

Long-Term Debt

As of September 30, 2019, we were in compliance with the financial and restrictive covenants of the 2018 Credit Facility. The following table provides outstanding balances of our debt instruments.

September 30, 2019 December 31, 2018
2018 Revolving Credit Facility $- $26,000
2018 First Lien Term Loan 148,000 154,000
2018 Second Lien Term Loan - 40,000
Convertible Senior Notes 172,500 -
Note payable - IVG 4,240 4,000
Total notes payable and long-term debt 324,740 224,000
Less debt discount and deferred finance charges (11,021) (3,285)
Less revolving credit facility - (26,000)
Less current maturities (14,240) (8,000)
$299,479 $186,715

2018 Credit Facility

The 2018 Credit Facility contains customary events of default including payment defaults, breaches of representations and warranties, covenant defaults, cross-defaults to certain other material indebtedness in excess of specified amounts, certain events of bankruptcy and insolvency, certain ERISA events, judgments in excess of specified amounts, and change in control defaults. The 2018 Credit Facility also contains certain negative covenants customary for facilities of these types including covenants that, subject to exceptions described in the 2018 Credit Facility, restrict our ability: (i) to pledge assets, (ii) to incur additional indebtedness, (iii) to pay dividends, (iv) to make distributions, (v) to sell assets, and (vi) to make investments. Refer to Note 20, “Dividends”, of Notes to Consolidated Financial Statements for further information regarding dividend restrictions.

2018 First Lien Credit Facility: The 2018 First Lien Term Loan and the 2018 Revolving Credit Facility bear interest at LIBOR plus a spread of 2.75% to 3.50% based on our senior leverage ratio. The 2018 First Lien Term Loan has quarterly required payments of $2.0 million beginning June 30, 2018, increasing to $3.0 million on June 30, 2020, and increasing to $4.0 million on June 30, 2022. The 2018 First Lien Credit Facility has a maturity date of March 7, 2023. The 2018 First Lien Term Loan is secured by a first priority lien on substantially all of the assets of the borrowers and the guarantors thereunder, including a pledge of our capital stock, other than certain excluded assets (the “Collateral”). In connection with the Senior Notes offering, we entered into a First Amendment (“the Amendment”) to the First Lien Credit Agreement, with Fifth Third Bank, as administrative agent, and other lenders and certain other lending other lending parties thereto. The Amendment was entered into primarily to permit us to issue up to $200 million of convertible senior notes, enter into certain capped call transactions in connection with the issuance of such notes and to use the proceeds from the issuance of the notes to repay amounts outstanding under our Second Lien Credit Agreement and use the remaining proceeds for acquisitions and investments. In connection with the Amendment, fees of $0.7 million were incurred. The 2018 First Lien Credit Facility contains certain financial covenants, which were amended in connection with the Convertible Senior Notes offering in the third quarter 2019. The covenants include maximum senior leverage ratio of 3.00x with step-downs to 2.50x, a maximum total leverage ratio of 5.50x with step-downs to 5.00x, and a minimum fixed charge coverage ratio of 1.20x. Based on an excess cash covenant for the facility, a principal payment of $4.5 million was due in the second quarter 2019. All parties agreed to waive the payment, resulting in consent fees of $0.1 million. The weighted average interest rate of the 2018 First Lien Term Loan was 5.04% at September 30, 2019. At September 30, 2019, we had no borrowings outstanding under the 2018 Revolving Credit Facility. The $50.0 million unused portion of the 2018 Revolving Credit Facility is reduced by letters of credit from Fifth Third Bank totaling $2.7 million, resulting in $47.3 million of availability under the 2018 Revolving Credit Facility at September 30, 2019.

2018 Second Lien Credit Facility: The 2018 Second Lien Credit Facility bore interest at a rate of LIBOR plus 7.00% and had a maturity date of March 7, 2024. The 2018 Second Lien Term Loan was secured by a second priority interest in the Collateral and was guaranteed by the same entities as the 2018 First Lien Term Loan. The 2018 Second Lien Credit Facility contained certain financial covenants including a maximum senior leverage ratio of 3.75x with step-downs to 3.50x, a maximum total leverage ratio of 4.75x with step-downs to 4.50x, and a minimum fixed charge coverage ratio of 1.10x. Based on an excess cash covenant for the facility, a $4.5 million principal payment was made in the second quarter 2019, resulting in $0.2 million loss on extinguishment of debt. We used a portion of the proceeds from the issuance of the Convertible Senior Notes to prepay all outstanding amounts related to the 2018 Second Lien Credit Facility in the third quarter 2019. The principal paid in the third quarter 2019 amounted to $35.5 million, and the transaction resulted in a $1.2 million loss on extinguishment of debt.

Convertible Senior Notes

In July 2019 we closed an offering of $172.5 million in aggregate principal amount of our 2.50% Convertible Senior Notes due July 15, 2024 (the “Convertible Senior Notes”). The Convertible Senior Notes bear interest at a rate of 2.50% per year, payable semiannually in arrears on January 15 and July 15 of each year, beginning on January 15, 2020. The Convertible Senior Notes will mature on July 15, 2024, unless earlier repurchased, redeemed or converted. The Convertible Senior Notes are senior unsecured obligations.

The Convertible Senior Notes are convertible into approximately 3,202,808 shares of our voting common stock under certain circumstances prior to maturity at a conversion rate of 18.567 shares per $1,000 principal amount of the Convertible Senior Notes, which represents a conversion price of approximately $53.86 per share, subject to adjustment under certain conditions, but will not be adjusted for any accrued and unpaid interest. Upon conversion, we may pay cash, shares of our common stock or a combination of cash and stock, as determined by us at our discretion. The conditions required to allow the holders to convert their Convertible Senior Notes were not met as of September 30, 2019.

The excess of the principal amount of the liability over its carrying amount (“debt discount”) is amortized to interest expense over the term of the Convertible Senior Notes using the effective interest rate method.

We incurred debt issue costs and allocated the total amount to the liability and equity components of the Convertible Senior Notes based on their relative values. The debt issue costs attributable to the liability component are amortized to interest expense over the term of the Convertible Senior Notes using the effective interest method. Issuance costs attributable to the equity component were netted with the equity component in stockholders’ equity.

In connection with the Convertible Senior Notes offering, we entered into privately negotiated capped call transactions with certain financial institutions. The capped call transactions have a strike price of $53.86 per and a cap price of $82.86 per, and are exercisable when and if the Convertible Senior Notes are converted. We paid $20.53 million for these capped calls and charged that amount to additional paid-in capital.

Note Payable – IVG

In September 2018, we issued a note payable to IVG’s former shareholders (“IVG Note”). The IVG Note is $4.0 million principal with 6.0% interest compounding annually and matures on March 5, 2020. All principal and accrued and unpaid interest under the IVG Note is subject to indemnification obligations of the sellers pursuant to the International Vapor Group Stock Purchase Agreement dated as of September 5, 2018. The carrying amount of the IVG Note is $4.2 million as of September 30, 2019.

Off-balance Sheet Arrangements

During the nine months ended September 30, 2019 we did not execute any forward contracts. During 2018 the Company executed various forward contracts, none of which met hedge accounting requirements, for the purchase of €14.5 million with maturity dates ranging from March 2018 to January 2019. At September 30, 2019, and December 31, 2018, we had forward contracts for the purchase of €0.0 million and €1.5 million, respectively.

Inflation

We believe that any effect of inflation at current levels will be minimal. Historically, we have been able to increase prices at a rate equal to or greater than that of inflation and believe that we will continue to be able to do so for the foreseeable future. In addition, we have been able to maintain a relatively stable variable cost structure for our products due, in part, to our successful procurement with regard to our tobacco products and, in part, to our existing contractual agreement for the purchase of our premium cigarette papers.

Market risk

As filed, 2,132 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Foreign Currency Sensitivity

There have been no material changes in our exposure to exchange rate fluctuation risk, as reported within our 2018 Annual Report on Form 10-K, during the period. Please refer to our ‘Quantitative and Qualitative Disclosures about Market Risk’ included in our 2018 Annual Report on Form 10-K filed with the SEC.

Credit Risk

There have been no material changes in our exposure to credit risk, as reported within our 2018 Annual Report on Form 10-K, during the three months ended September 30, 2019. Please refer to our ‘Quantitative and Qualitative Disclosures about Market Risk’ included in our 2018 Annual Report on Form 10-K filed with the SEC.

Interest Rate Sensitivity

Our March 2018 refinancing resulted in all of our long-term debt instruments having variable interest rates that fluctuate with market rates. To reduce the volatility of future cash flows, we entered into interest rate swap agreements with lenders under the 2018 Credit Facility in March 2018. At September 30, 2019, $70 million of our outstanding long-term debt carrying variable rates is covered by the interest rate swap agreements and, thus, effectively bears interest at a fixed rate. We believe the effect, if any, of reasonably possible near-term changes in interest rates on our consolidated financial position, results of operations, or cash flows would not be significant. A 1% increase in the interest rate would change pre-tax income by approximately $0.8 million per year. Refer to Note 4, “Derivative Instruments”, of Notes to Consolidated Financial Statements for additional information regarding the interest rate swaps.

In July 2019, we issued Convertible Senior Notes with an aggregate principal amount of $172.5 million. We carry the Convertible Senior Notes at face value less amortized discount on the balance sheet. Since the Convertible Senior Notes bear interest at a fixed rate, we have no financial statement risk associated with changes in interest rates. However, the fair value of the Convertible Senior Notes changes when the market price of our stock fluctuates, or interest rates change.

Controls and procedures

As filed, 1,325 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

We have carried out an evaluation under the supervision, and with the participation of, our management including our Chief Executive Officer (“CEO”), Chief Financial Officer (“CFO”), and Chief Accounting Officer (“CAO”), of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act of 1934, as amended (the “Act”)) as of September 30, 2019. Based upon the evaluation, our CEO, CFO, and CAO concluded our disclosure controls and procedures are effective to provide reasonable assurance that information required to be disclosed by us in the reports we file or submit under the Act is: (i) recorded, processed, summarized, and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms and (ii) accumulated and communicated to our management, including our principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosures.

There have been no changes in the Company’s internal control over financial reporting during the most recent fiscal quarter which have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

Risk factors

As filed, 1,965 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

In addition to the other information set forth in this report, carefully consider the factors discussed in the ‘Risk Factors’ section contained in our 2018 Annual Report on Form 10-K. There have been no material changes to the Risk Factors set forth in the 2018 Annual Report on Form 10-K with the exception of the following update for the risk factor “Some of our products are subject to developing and unpredictable regulation”:

Some of our NewGen products marketed through our Nu-X subsidiary and similar third-party products sold through our NewGen distribution vehicles may be subject to uncertain federal, state and local regulations concerning hemp, CBD and other non-tobacco consumable products. Enforcement initiatives by those authorities are therefore unpredictable and impossible to anticipate. We anticipate that all levels of government are likely to seek in some way to regulate these products, but the type, timing, and impact of such regulations remains uncertain. Accordingly, we cannot give any assurance that such actions would not have a material adverse effect on this emerging business.

We currently and plan in the future to commercialize in the United States a variety of products containing hemp-derived CBD. While the Agriculture Improvement Act of 2018, or the Farm Bill, exempted hemp and hemp-derived products from the Controlled Substances Act, or the CSA, any such product commercialization may become subject to various laws, including the Farm Bill, the Food, Drug and Cosmetic Act, or the FD&CA, the Dietary Supplement Health and Education Act, or DSHEA, applicable state and/or local laws, and FDA regulations. We intend to offer hemp-derived CBD products in full compliance with laws and regulations. Nevertheless, violations of any such law or regulation could result in warning letters, significant fines, penalties, administrative sanctions, injunctions, convictions or settlements arising from civil proceedings initiated.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2019-09-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2019-07-01 to 2019-09-30$96.8mus-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
Revenue9 months2019-01-01 to 2019-09-30$281.8mus-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
Cost of revenue3 months2019-07-01 to 2019-09-30$54.0mus-gaap:CostOfGoodsAndServicesSold
Cost of revenue9 months2019-01-01 to 2019-09-30$157.3mus-gaap:CostOfGoodsAndServicesSold
Gross profit3 months2019-07-01 to 2019-09-30$42.8mus-gaap:GrossProfit
Gross profit9 months2019-01-01 to 2019-09-30$124.5mus-gaap:GrossProfit
Selling, general and administrative3 months2019-07-01 to 2019-09-30$29.8mus-gaap:SellingGeneralAndAdministrativeExpense
Selling, general and administrative9 months2019-01-01 to 2019-09-30$79.5mus-gaap:SellingGeneralAndAdministrativeExpense
Operating income3 months2019-07-01 to 2019-09-30$13.0mus-gaap:OperatingIncomeLoss
Operating income9 months2019-01-01 to 2019-09-30$45.0mus-gaap:OperatingIncomeLoss
Income tax3 months2019-07-01 to 2019-09-30$2.2mus-gaap:IncomeTaxExpenseBenefit
Income tax9 months2019-01-01 to 2019-09-30$7.0mus-gaap:IncomeTaxExpenseBenefit
Net income3 months2019-07-01 to 2019-09-30$6.3mus-gaap:NetIncomeLoss
Net income9 months2019-01-01 to 2019-09-30$26.0mus-gaap:NetIncomeLoss
Diluted EPS3 months2019-07-01 to 2019-09-30$0.31us-gaap:EarningsPerShareDiluted
Diluted EPS9 months2019-01-01 to 2019-09-30$1.32us-gaap:EarningsPerShareDiluted
Basic EPS3 months2019-07-01 to 2019-09-30$0.32us-gaap:EarningsPerShareBasic
Basic EPS9 months2019-01-01 to 2019-09-30$1.33us-gaap:EarningsPerShareBasic
Diluted shares (weighted)3 months2019-07-01 to 2019-09-3020,067,413 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Diluted shares (weighted)9 months2019-01-01 to 2019-09-3019,777,163 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow9 months2019-01-01 to 2019-09-30$20.0mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure3 months2019-07-01 to 2019-09-30$2.1mus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Capital expenditure9 months2019-01-01 to 2019-09-30$4.1mus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Dividends paid9 months2019-01-01 to 2019-09-30$2.6mus-gaap:PaymentsOfDividendsCommonStock
Cash and equivalentsAt period end2019-09-30$81.1mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2019-09-30$202.6mus-gaap:AssetsCurrent
Total assetsAt period end2019-09-30$454.3mus-gaap:Assets
Current liabilitiesAt period end2019-09-30$43.3mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2019-09-30$358.9mus-gaap:Liabilities
Long-term debtAt period end2019-09-30$299.5mus-gaap:LongTermDebtNoncurrent
Shareholders' equityAt period end2019-09-30$95.3mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001140361-19-019729. Last ingested by Listed: Nov 10, 2026, 02:39 ET. Listed shows no prices and gives no investment advice.